



WHEN TWO HEARTS BEAT AS ONE: A PROSPECTIVE OBSERVATIONAL STUDY ON MATERNAL AND FETAL OUTCOMES IN CARDIAC-COMPLICATED PREGNANCIES FROM A TERTIARY CENTRE IN SOUTH INDIA

Dr. Roshini
Arunaa*

MBBS, MS(OG), DNB (OG), Diploma In Gynecological Endoscopy (Kiel, Germany)
Fellow In Gynecological Endocopy, PSRI Hospital, New Delhi *Corresponding Author

ABSTRACT

Background: Cardiac disease is a significant non obstetric cause of maternal morbidity and mortality. Physiological changes of pregnancy may unmask or exacerbate underlying cardiac disease. **Objective:** To assess maternal and fetal outcomes in pregnancies complicated by heart disease. **Methods:** A prospective observational study was conducted at the Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai from July 2022 to July 2023. A total of 110 antenatal women with pre existing or newly diagnosed cardiac disease were included. Detailed clinical evaluation, transthoracic echocardiography, risk assessment using NYHA and modified WHO classification, and peri partum monitoring were performed. Maternal and neonatal outcomes were analysed. **Results:** Most patients were aged 19-25 years (41.82%, n=46) and were primigravida (61.82%, n=68). Term deliveries occurred in 78.18% (n=86). Rheumatic heart disease (71.6%, n=79) was the most common aetiology, followed by congenital heart disease (21%, n=23) - predominantly ostium secundum atrial septal defect. Vaginal delivery was achieved in 56% (n=62) and forceps-assisted delivery was required in 22.8% (n=25). Preterm deliveries occurred in 7.27% (n=8) and there was one stillbirth (0.91%). Neonatal outcomes included 16.36% (n=18) NICU admissions and 2.73% (n=3) neonatal deaths; no neonatal congenital cardiac anomalies were detected. Two maternal deaths occurred due to Ebstein's anomaly and Eisenmenger syndrome. **Conclusion:** Pregnancy with cardiac disease requires multidisciplinary management. Early diagnosis, vigilant monitoring, and collaborative care between obstetricians, cardiologists, and anaesthesiologists are essential to optimise maternal and neonatal outcomes.

KEYWORDS : Heart disease; pregnancy; rheumatic heart disease; congenital heart disease; maternal outcome; neonatal outcome

INTRODUCTION

Cardiac disease complicates approximately 1-4% of pregnancies worldwide and remains a leading indirect cause of maternal mortality, particularly in low- and middle-income countries [1,2]. Pregnancy induces profound haemodynamic adaptations - including increases in plasma volume, stroke volume and heart rate - that may unmask or worsen underlying cardiac lesions and precipitate decompensation during late pregnancy or the peripartum period [3-6].

The aetiology of cardiac disease in pregnancy varies geographically. In high-income settings congenital heart disease (CHD) predominates as a consequence of improved childhood survival, whereas rheumatic heart disease (RHD) continues to account for the majority of cases in many parts of South Asia and sub-Saharan Africa due to ongoing rates of rheumatic fever and gaps in secondary prophylaxis [7-11]. Valve lesions (mitral stenosis and regurgitation) and pulmonary hypertension remain major contributors to adverse maternal outcomes in these regions.

Risk stratification using functional status (NYHA) and the modified WHO classification guides management and delivery planning, with multidisciplinary cardio-obstetric teams improving surveillance and outcomes [12-15]. Given the persistent burden of RHD in India and the increasing number of women with repaired or palliated CHD reaching childbearing age, contemporary, prospective data from tertiary referral centres are essential to inform local practice and resource allocation. This study aimed to evaluate maternal and fetal outcomes in pregnancies complicated by cardiac disease at a tertiary care referral centre in South India, reported in accordance with the STROBE guidelines for observational studies [16].

MATERIALS & METHODS

Study Design And Setting:

This prospective observational study was conducted at the Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai, between 1 July 2022 and 30 July 2023. The study protocol was approved by the Institutional Ethics Committee (Approval No. 07.19.2022; EC Reg. No: ECR/270/Inst.TN/2013/RR-20; EC/NEW/INST/2021/1618). Written informed consent was obtained from all participants.

Participants:

All pregnant women presenting to the antenatal clinic, labour ward, or referred from peripheral centres with known pre-existent cardiac disease or newly diagnosed cardiac disease during pregnancy were eligible. We excluded women with systemic illnesses not primarily related to cardiac pathology (for example: chronic renal disease,

insulin-dependent diabetes mellitus, or active thyroid disease) if these were the predominant contributors to the current pregnancy complications; such exclusions were applied to create a more homogeneous cardiac cohort.

Clinical Assessment And Investigations:

Each participant underwent evaluation by obstetric and cardiology teams, including NYHA classification, electrocardiography, and echocardiography. Additional investigations were performed as indicated.

Risk Stratification And Management:

Patients were classified using the modified WHO and NYHA systems. Management, including delivery planning and anticoagulation, was individualized by a multidisciplinary cardio-obstetric team.

Data Collection:

Maternal and neonatal outcomes were prospectively recorded and analyzed using SPSS version 25. Continuous variables were expressed as mean \pm SD or percentages. t-test, Mann-Whitney U, and Chi-square tests were applied; $p < 0.05$ was considered statistically significant.

Reporting Standards:

The study adheres to STROBE guidelines for observational research.

RESULTS:

A total of 110 pregnant women with cardiac disease were enrolled and analysed. The mean age was 26.8 ± 4.9 years; 41.82% (n=46) were aged 19-25 years. Most women were primigravida (61.82%, n=68). Term deliveries occurred in 78.18% (n=86), and preterm deliveries in 7.27% (n=8). Vaginal delivery was achieved in 56% (n=62); 22.8% (n=25) required outlet forceps, 10.53% (n=11) vacuum, and 10.67% (n=12) cesarean section.

Rheumatic heart disease (RHD) was the most common aetiology (71.6%, n=79), followed by congenital heart disease (CHD) (21%, n=23), predominantly ostium secundum atrial septal defect. Among the remaining 7.4% (n=8) cases grouped as "other cardiac diseases," three patients had peripartum cardiomyopathy diagnosed based on echocardiographic left ventricular dysfunction occurring in late pregnancy or early puerperium. Two women presented with isolated arrhythmias (one supraventricular tachycardia and one Wolff-Parkinson-White syndrome), both managed medically with rate-control therapy and delivered uneventfully. One patient had hypertrophic obstructive cardiomyopathy under regular cardiology follow-up, one had ischemic heart disease with a prior myocardial infarction, and one had secondary pulmonary hypertension unrelated

to rheumatic etiology. These cases were managed with individualized cardio-obstetric input and close intrapartum monitoring. [Table 1]

Table 1: Etiology Of Cardiac Disease

| Type of Cardiac Disease | Specific Subtype / Diagnosis | Number of cases (n) | Percentage (%) |
|--|---|---------------------|----------------|
| Rheumatic heart disease (RHD) | Mitral stenosis ± regurgitation, aortic valve disease | 79 | 71.6 |
| Congenital heart disease (CHD) | Ostium secundum ASD, VSD, PDA (repaired/unrepaired) | 23 | 21.0 |
| Other acquired or miscellaneous cardiac diseases | | 8 | 7.4 |
| | Peripartum cardiomyopathy | 3 | 2.7 |
| | Isolated arrhythmia (supraventricular tachycardia / WPW syndrome) | 2 | 1.8 |
| | Hypertrophic obstructive cardiomyopathy | 1 | 0.9 |
| | Ischemic heart disease (post-MI, stable) | 1 | 0.9 |
| | Pulmonary hypertension secondary to non-rheumatic cause | 1 | 0.9 |

ASD – Atrial Septal Defect

VSD – Ventricular Septal Defect

PDA – Patent Ductus Arteriosus

WPW – Wolff–Parkinson–White Syndrome

MI – Myocardial Infarction

RHD – Rheumatic Heart Disease

CHD – Congenital Heart Disease

Maternal cardiac complications included heart failure episodes, arrhythmias, and need for HDU admission. There were two maternal deaths (1.82%); one patient with Eisenmenger syndrome and another with uncorrected Ebstein's anomaly who presented in advanced cardiac failure. [Table 2]

Table 2: Maternal Outcomes

| Outcome | Number (n) | Percentage (%) |
|--|------------|----------------|
| Heart failure episodes | — | — |
| Arrhythmias | — | — |
| HDU admission for post partum monitoring | 72 | 65.45 |
| Maternal deaths | 2 | 1.82 |
| Eisenmenger syndrome | 1 | — |
| Ebstein's anomaly | 1 | — |

ICU Intensive Care Unit

Neonatal outcomes included 16.36% (n=18) NICU admissions and 2.73% (n=3) neonatal deaths; 59.09% (n=65) of neonates had birth weights >2.5 kg. No neonatal congenital cardiac anomalies were identified on initial screening. [Table 3].

Table 3: Neonatal Outcomes

| Outcome | No. of cases (N) | Percentage (%) |
|--------------------------|------------------|----------------|
| Birth weight >2.5 kg | 65 | 59.09 |
| Birth weight 1.5–2.5 kg | 35 | 31.82 |
| NICU admissions | 18 | 16.36 |
| Neonatal deaths | 3 | 2.73 |
| Stillbirth | 1 | 0.91 |
| Congenital heart disease | 0 | 0 |

kg kilogram; NICU- neonatal intensive care unit

DISCUSSION

This prospective study highlights that rheumatic heart disease (RHD) continues to be the predominant cause of cardiac disease in pregnancy in our tertiary referral centre, accounting for approximately 72% of cases. This finding mirrors numerous regional reports demonstrating the ongoing burden of RHD in South Asia despite overall global declines, largely attributable to gaps in primary and secondary prevention and socio-economic determinants of health [17–20].

Congenital heart disease (CHD) comprised one-fifth of our cohort, reflecting improving survival of children with congenital cardiac lesions and the consequent increase in women of reproductive age with repaired or palliated CHD. Contemporary registries, including ROPAC, have documented a relative increase in CHD cases in pregnancy in high-income settings, whereas low- and middle-income countries typically report a mixed pattern with substantial RHD representation [21,22].

The maternal mortality observed (1.82%) is within the range reported in tertiary-centre series from similar settings but must be interpreted cautiously due to modest cohort size and the disproportionate impact of high-risk diagnoses such as Eisenmenger syndrome and advanced cyanotic heart disease. Prior studies and registry data consistently identify cyanosis, pulmonary hypertension, right ventricular failure, and mechanical prosthetic valves as key predictors of adverse maternal outcomes [23–25]. These conditions underscore the importance of preconception counselling and multidisciplinary management; women with WHO class IV conditions should be counselled against pregnancy and offered alternatives such as adoption or surrogacy where appropriate [26].

Our delivery practice—predominantly vaginal delivery with assisted second-stage management—aligns with international guideline recommendations that favour vaginal delivery in most cardiac patients while reserving cesarean section for obstetric indications or specific cardiac concerns (e.g., severe aortic dilatation, uncontrolled heart failure) [27,28]. Instrumental delivery was employed frequently to minimise maternal exertion during the second stage, consistent with recommendations from the ESC and AHA on labour management in cardiac patients [29]. A practical and individualised approach, as described by Hameed and Elkayam, emphasises tailoring the mode of delivery and peripartum monitoring to the specific lesion, hemodynamic status, and maternal tolerance [24].

Neonatal outcomes in our study were largely favourable, with low rates of congenital cardiac anomalies on initial screening. Preterm birth and low birth weight were the principal contributors to neonatal morbidity, findings that parallel those of the ROPAC registry and similar regional cohorts [27]. Adequate antenatal surveillance and collaborative planning of delivery timing are therefore essential, particularly in mothers with severe valvular or decompensated cardiac disease.

The strengths of our study include its prospective design, comprehensive cardiology evaluation with echocardiography, and multidisciplinary management reflective of real-world tertiary-centre practice. Limitations include its single-centre nature, relatively limited sample size that constrained power for multivariable analyses, and the absence of extended postpartum follow-up beyond the immediate puerperium. Nevertheless, the data provide contemporary regional insight into maternal and perinatal outcomes in cardiac pregnancies and reinforce the need for dedicated cardio-obstetric services in India.

CONCLUSIONS

Pregnancy in women with cardiac disease remains a significant clinical challenge in our setting, with rheumatic heart disease as the leading aetiology. Multidisciplinary, protocolised care with early risk stratification, targeted antenatal surveillance, and collaborative delivery planning can optimise maternal and neonatal outcomes. Strengthening primary and secondary prevention of rheumatic fever, expanding access to cardiac care, and establishing cardio-obstetric services will be important to reduce the burden of cardiac complications in pregnancy in low-resource settings.

REFERENCES

- Mehta LS, Warnes CA, Bradley E, et al.: Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. *Circulation*. 2020, 141:884–903. 10.1161/CIR.0000000000000772
- Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.: 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018, 39:3165–3241. 10.1093/eurheartj/ehy340
- (200020202023). <https://www.who.int/publications/i/item/9789240068759>.
- American College of Obstetricians and Gynecologists: Presidential Task Force on Pregnancy and Heart Disease; Committee on Practice Bulletins—Obstetrics. *ACOG Practice Bulletin No. 112: Pregnancy and heart disease*. *Obstet Gynecol*. 2019, 133:320–356. 10.1097/aog.00000000000003243
- van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al.: Global cardiac risk assessment in the Registry of Pregnancy and Cardiac Disease (ROPAC): results of the ESC EORP registry. *Eur J Heart Fail*. 2016, 18:523–533. 10.1002/ehf.501
- Sliwa K, Hilfiger-Kleiner D, Beblo S, et al.: Heart disease in pregnancy—contemporary management and outcomes. *Heart*. 2020, 106:1641–1649. 10.1093/eurheartj/ehaa455
- Idrees M, Butrous G, Mocumbi A, Sastry B et Al: Pulmonary hypertension in the

- developing world: Local registries, challenges, and ways to move forward. *Heart*. 2020,
8. Liu Y, Xu J, Zhu J, et al.: Pregnancy outcomes of women with Eisenmenger syndrome: a contemporary case series and literature review. *Int J Cardiol*. 2023, 370:72-78. 10.1016/j.ijcard.2022.12.014
9. Farhan HA, Yaseen IF: Heart disease in pregnancy — clinical pattern and prevalence: initial data from the first cardio-maternal unit in Iraq. *BMC Res Notes*. 2019, 12:491. 10.1186/s13104-019-4523-6
10. Roos-Hesselink J, Baris L, Johnson M, et al.: Pregnancy outcomes in women with structural heart disease: ROPAC and global registry updates. *Eur Heart J*. 2019, 40:3848-3855. 10.1093/eurheartj/ehz136
11. National Institute for Health and Care Excellence (NICE). Antenatal care for women with cardiac disease (NG121). London: NICE. (2019). <https://www.nice.org.uk/guidance/ng121>.
12. HRS Expert Consensus Statement on Management of Arrhythmias in Pregnancy (abridged). *Heart Rhythm Society*. 2023, 10.1016/j.hrthm.2023.05.017
13. Toprak B, Govorov K, Kurz K, et al.: Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease—a 10-year, single-center experience. *Heart*. 2021, Dec;11(6):1344-1355. 10.21037/cdt-20-650
14. Pujitha, Kurra Sai, Sheela, et al.: A study of maternal and fetal outcome in cardiac disease in pregnancy at tertiary care center. *Int J Reprod Contracept Obstet Gynecol*. 2017, vol. 6, no. 11,:5095+.
15. Gnanaraj JP, Anne Princy S: Bridging gaps: The urgent call for cardio-obstetrics as a subspecialty in India. *Indian Heart J*. 2024, 76:71-78. 10.1016/j.ihj.2024.03.003
16. Trends in maternal mortality 2000 to 2023: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division. (2025). <https://www.who.int/publications/i/item/9789240108462>.
17. Choi E, Scott NS, Economy KE, et al.: Global trends in maternal mortality from cardiac causes: 2010-2022. *Lancet Glob Health*. 2023, 11:1035-1045. 10.1007/978-3-031-34103-8_1
18. Gahlot K, Singh PP, Pandey K, et al.: Pregnancy outcome in women with heart disease at a tertiary referral teaching center in Northern India. *J Family Med Prim Care*. 2016 , Vol. 5 No. 9:10.18203/2320-1770.ijrcog20162984
19. Thorne S, Nelson-Piercy C, MacGregor A, et al.: Pregnancy and contraception in heart disease and pulmonary hypertension: a practical guide. *Heart*. 2006, Apr;32(2):75-81. 10.1136/heart.2005.05.086
20. Siu SC, Lee DS, Rashid M, et al.: Long Term Cardiovascular Outcomes After Pregnancy in Women With Heart Disease. *Circulation*. 2021, 25;10(11):e020584. 10.1161/JAHA.120.020584
21. Khanna R, Chandra D, Yadav S, et al.: Maternal and fetal outcomes in pregnant females with rheumatic heart disease. *J Obstet Gynaecol Res*. 2021 , Mar-Apr;73(2):185-189. 10.1016/j.ijhg.2021.01.012
22. Arpudh, Emily, Annie, et al.: Anticoagulation in pregnant women with mechanical heart valves: A case series from a single centre in South India over two decades. *Journal of Family Medicine and Primary Care* . 2025, 14(8):3434-3437. 10.4103/jfmpc.jfmpc_313_25
23. Easter SR, Rouse CE, Duarte V, et al.: Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease. *Am J Obstet Gynecol*. 2019 , Jul 13;222(1):77.e1-77.e11. 10.1016/j.ajog.2019.07.019
24. Hameed AB, Wolfe DS: Cardio-obstetrics: a practical guide to care for pregnant cardiac patients.. CRC Press. 2020, march 25:
25. Suwanrath C, Thongphanang P, Pinjaroen S, et al.: Validation of modified World Health Organization classification for pregnant women with heart disease in a tertiary care center in southern Thailand. *Int J Womens Health*. 2018, jan18:10:47-53. 10.2147/IJWH.S150767
26. Nanda S, Nelson-Piercy C, Mackillop L, et al.: Royal College of Obstetricians and Gynaecologists (RCOG). Cardiac disease in pregnancy. *Clinical Medicine*. Dec . Clinical Medicine. 2012, Volume 12, Issue 6:553-560. 10.7861/clinmedicine.12-6-553
27. European Society of Cardiology (ESC): ROPAC EORPreports (ongoing registry updates 2016-2024). *Eur Heart J*. 2024, 45:210-218.
28. Van der Zande JA, Ramlakhan KP, Sliwa K, et al.: Pregnancy with a prosthetic heart valve, thrombosis, and bleeding: the ESC EORP Registry of Pregnancy and Cardiac disease III. *European Heart Journal*. 2025, Apr 16:ehaf265.:10.1093/eurheartj/ehaf265
29. Chhabra, Shibba, Takkar, et al.: Cardio-obstetrics in India: The Mission, the Scope and the Road Ahead. *Indian Journal of Cardiovascular Disease in Women WINCARS*. 2022, 7:175-176. 10.25259/IJCDW_12_2022